© 2004


Volume 2: Novel Technologies and Therapeutic Use

  • G. Subramanian

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Ralf Ostendorp, Christian Frisch, Margit Urban
    Pages 13-52
  3. X. K. Deng, T. Shantha Raju, K. John Morrow Jr
    Pages 53-78
  4. Maxime Moulard, Mei-Yun Zhang, Dimiter S. Dimitrov
    Pages 105-117
  5. David Azria, Christel Larbouret, Bruno Robert, Mahmut Ozsahin, Jean-Bernard Dubois, André Pèlegrin
    Pages 119-139
  6. Francois Hirsch, Olivier Deas, Gabrielle Carvalho, Antoine Dürrbach, Dominique Thierry, Alain Chapel
    Pages 141-155
  7. Alcide Barberis, Adrian Auf Der Maur, Kathrin Tissot, Peter Lichtlen
    Pages 157-168
  8. Sylvie Ménard, Serenella M. Pupa, Manuela Campiglio, Elda Tagliabue
    Pages 183-187
  9. Delphine Loirat, Sylvie Jacod, Aurélie Boyer, Fabrice Auzelle, Andrès McAllister, Jean-Pierre Abastado et al.
    Pages 189-197
  10. Sophie Siberil, Jean-Luc Teillaud
    Pages 199-215
  11. Back Matter
    Pages 217-232

About this book


It is now over one hundred years since von Behring and Kitsato first concluded experiments that led to the use of passive immunisation, employing antibodies raised in animals against tetanus and diphtheria toxins. The advancement of technology both in manufacturing purity product in a cost effective way and the clinical research has proved that antibodies are one ofthe most successful products in biotechnology. Monoclonal antibodies account for between one-third and one-halfof all pharmaceutical products in development and human clinical trials. Both the nature of monoclonal antibody therapies and the relatively large size of the monoclonal antibody dictate the production requirements, for many ofthese therapeutics the monoclonal antibody product will be 100 kilogrammes or more per year. It is widely acknowledged that there is currently a worldwide shortage of biomanufacturing capacity, and the active pharmaceutical ingredient material requirements for these products are expected to increase. Thus the industry is looking for new sources and extensive studies are being carried out not only for alternative technology to meet the needs but also to reveal the new therapeutic applicationsofantibodies. This book brings to the forefront current advances in novel technologies for the manufacturing of monoclonal antibodies and also their extensive clinical importance. The first four chapters give an overview of the new technologies and the successful application in the manufacture of monoclonal antibodies with clinical purity. The next chapters address the application of antibodies in cancer therapy and functional genomic therapy.


HIV cancer cancer therapy cells development future immunotherapy kinetics macrophages manufacturing pharmaceutical pharmacokinetics research safety tissue

Editors and affiliations

  • G. Subramanian
    • 1
  1. 1.Littlebourne, KentUK

Bibliographic information

Industry Sectors
Health & Hospitals